Skip to main content

Bilateral Wilms Tumors That Grow During Chemo Mostly Stromal-Predominant

Medically reviewed by Carmen Pope, BPharm. Last updated on April 17, 2024.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, April 17, 2024 -- Bilateral Wilms tumors (BWTs) that increase in size during neoadjuvant chemotherapy, especially in younger patients, are most often stromal-predominant, according to a study published online March 27 in the Journal of the National Cancer Institute.

Colton Duncan, from the Dana-Farber Cancer Institute/Boston Children's Hospital, and colleagues conducted a retrospective, single-institution study to examine whether initial chemotherapy response is associated with tumor histology among patients with BWT who underwent surgery from January 2000 to March 2022. A total of 68 patients were eligible for the study.

The researchers found that the odds ratio for being stromal-predominant versus any other histological subtype was 19.5 for tumors that increased in size. Compared with all other histologic subtypes, patients with stromal-predominant tumors had the youngest age at diagnosis (mean, 18.8 months). For confirming stromal-predominant histology, the predictive value of a tumor growing, combined with patient age younger than 18 months, was 85.7 percent.

"Wilms tumor with unfavorable outcomes actually do generally respond well, at least initially, to the chemotherapy," coauthor Andrew Davidoff, M.D., from St. Jude Children's Research Hospital in Memphis, Tennessee, said in a statement. "Whereas, at the other end of the spectrum, we have this extremely favorable type, this stromal-predominant tumor, that has typically good outcomes despite not responding very well to the chemotherapy."

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted April 2024

Read this next

AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours

WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...

Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million

TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...

Patient–Primary Care Provider Language Concordance Tied to Better Outcomes

TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.